Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Botulinum Toxins is addressed separately in medical policy 00012.

Note: Occipital Nerve Stimulation is addressed separately in medical policy 00253.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers surgical deactivation of trigger sites for the treatment of migraine and non-migraine headache to be investigational.*

Policy Guidelines
International Headache Society classification criteria (3rd edition, 2018) are listed in Table PG1.

Table PG1. International Headache Society Classification Criteria for Migraines

<table>
<thead>
<tr>
<th>Classification Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Migraine without aura</strong></td>
</tr>
<tr>
<td>Description</td>
</tr>
<tr>
<td>Recurrent headache disorder characterized by attacks lasting 4 to 72 hours.</td>
</tr>
<tr>
<td>Diagnostic criteria</td>
</tr>
<tr>
<td>A. At least 5 attacks fulfilling criteria B through D</td>
</tr>
<tr>
<td>B. Headache attacks lasting 4 to 72 hours (untreated or successfully treated)</td>
</tr>
</tbody>
</table>

*Based on review of available data, the Company considers surgical deactivation of trigger sites for the treatment of migraine and non-migraine headache to be investigational.*
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

C. At least 2 of the following 4 characteristics: 1. unilateral location; 2. pulsating quality; 3. moderate or severe pain intensity; 4. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs)

D. During headache, at least 1 of the following: 1. nausea and/or vomiting; 2. photophobia and phonophobia

E. Not better accounted for by another ICHD-3 diagnosis

Migraine with aura

Description

Recurrent attacks, lasting minutes, of unilateral fully reversible visual, sensory or other central nervous system symptoms that usually develop gradually and are usually followed by headache and associated migraine symptoms.

Diagnostic criteria

A. At least 2 attacks fulfilling criteria B and C

B. One or more of the following fully reversible aura symptoms: 1. visual; 2. sensory; 3. speech and/or language; 4. motor; 5. brainstem; 6. retinal

C. At least 3 of the following 6 characteristics: 1. at least 1 aura symptom spreads gradually over ≥5 minutes; 2. 2 or more aura symptoms occur in succession; 3. each individual aura symptom lasts 5 to 60 minutes; 4. at least 1 aura symptom is unilateral; 5. at least 1 aura symptom is positive; 6. the aura is accompanied, or followed within 60 minutes, by headache

D. Not better accounted for by another ICHD-3 diagnosis, and transient ischemic attack has been excluded.


Background/Overview
Migraine Headache
Migraine is a common headache disorder with a prevalence in the United States of approximately 18% in women and 6% in men. According to the International Headache Society (2018), migraine headache is a recurrent disorder with attacks lasting 4 to 72 hours. Typical features of migraine headaches include unilateral location, pulsating quality, moderate or severe intensity, and associated symptoms such as nausea, photophobia, and/or phonophobia.

Treatment
A variety of medications are used to treat acute migraine episodes. These include medications taken at the onset of an attack to abort the attack (triptans, ergotamines), and medications to treat the pain and other symptoms of migraines once they are established (nonsteroidal anti-inflammatory drugs, narcotic analgesics, antiemetics). Prophylactic medication therapy may be appropriate for people with migraines that occur more than 2 days per week. In addition to medication, behavioral treatments such as relaxation and cognitive therapy are used to manage migraine headache. Moreover, botulinum toxin type A injections are a U.S. Food and Drug Administration (FDA) approved treatment for chronic migraine (migraines occurring on at least 15 days a month for at least 3 months).

Surgical Deactivation
Surgical deactivation of trigger sites is another proposed treatment of migraine headache. The procedure was developed by a plastic surgeon (Bahman Guyuron, MD), following observations that some patients who had cosmetic forehead lifts reported improvement or elimination of migraine symptoms postsurgery. The procedure is based on the theory that migraine headaches arise due to inflammation of trigeminal nerve branches in the head and neck caused by irritation of the surrounding musculature, bony foramen, and perhaps fascia bands. Accordingly, surgical treatment of migraines involves removing the relevant nerve sections, muscles, fascia, and/or vessels. The treatment is also based on the theory there are specific migraine trigger sites and that these sites can be located in individual patients. In studies conducted by Guyuron’s research group, clinical evaluation and diagnostic injections of botulinum toxin have been used to locate trigger sites. The specific surgical procedure varies according to the patient’s migraine trigger site. The surgical procedures are performed under general anesthesia in an ambulatory care setting and take an average of 1 hour.
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

Surgical procedures have been developed at 4 trigger sites: frontal, temporal, rhinogenic, and occipital. Frontal headaches are believed to be activated by irritation of the supratrochlear and suborbital nerves by glabellar muscles or vessels. The surgical procedure involves the removal of the glabellar muscles encasing these nerves. Fat from the upper eyelid is used to fill the defect in the muscles and shield the nerve. Temporal headaches may be activated by inflammation of the zygomatico-temporal branch of the trigeminal nerve by the temporalis muscles or vessels adjacent to the nerve. To treat migraines located at this trigger site, a segment (≈2.5 cm) of the zygomatico-temporal branch of the trigeminal nerve is removed endoscopically. Rhinogenic headaches may involve intranasal abnormalities (eg, deviated septum), which may irritate the end branches of the trigeminal nerve. Surgical treatment includes septoplasty and turbinectomy. Finally, occipital headaches may be triggered by irritation of the occipital nerve caused by the semispinalis capitis muscle or the occipital artery. Surgery consists of removal of a segment of the semispinalis capitis muscle medial to the greater occipital nerve approximately 1 cm wide and 2.5 cm long, followed by insertion of a subcutaneous flap between the nerve and the muscle to avoid nerve impingement.

Non-Migraine Headache
It has been proposed that other types of headaches (eg, tension headaches) may also be triggered by irritation of the trigeminal nerve.

Treatment
Although the mechanism of action is less well established for headaches other than migraine, it is possible that surgical treatment of trigger sites may also be beneficial for some non-migraine headaches.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Surgical deactivation of headache triggers is a surgical procedure and, as such, is not subject to regulation by the FDA.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice.
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Migraine is a common headache disorder that is treated using various medications, which can be taken at the onset of an attack and/or for migraine prophylaxis. Other treatments include behavioral treatments and botulinum toxin injections. Surgical deactivation of trigger sites is another proposed treatment. Surgical deactivation is based on the theory that migraine headaches arise due to inflammation of the trigeminal nerve branches in the head and neck and that specific trigger sites can be identified in individual patients. Surgical deactivation has also been proposed for other types of headaches (eg, tension headaches).

Summary of Evidence
For individuals who have migraine headaches who receive surgical deactivation of headache trigger sites, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, morbid events, and treatment-related morbidity. Three RCTs have been published; only 1 used a sham control and blinded patients to the treatment group. All 3 reported statistically significantly better outcomes at 12 months in patients who received decompression surgery for migraine headache than the control intervention. However, the trials were subject to methodologic limitations (eg, unclear and variable patient selection processes, variability in surgical procedures depending on trigger site). In addition, findings from 2 trials with no blinding or sham-controls were subject to the placebo effect. Additional sham-controlled randomized studies are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have non-migraine headaches who receive surgical deactivation of headache trigger sites, the evidence includes no published studies. Relevant outcomes are symptoms, change in disease status, morbid events, and treatment-related morbidity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US
Surgical Deactivation of Headache Trigger Sites

Policy #  00683
Original Effective Date:  08/14/2019
Current Effective Date:  09/12/2022

representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Headache Society
The American Headache Society (2013) approved a list of 5 items that provide low value in headache medicine. This list was produced as part of the American Board of Internal Medicine Foundation’s Choosing Wisely initiative. One of the 5 recommendations was: “Don’t recommend surgical deactivation of migraine trigger points outside of a clinical trial.” The 2013 document stated that the value of this procedure is still a research question and that large, multicenter randomized controlled trials with long-term follow-up are needed to provide accurate information on its benefits and harms.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02351544</td>
<td>Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches</td>
<td>100</td>
<td>Dec 2023 (Status=Recruiting)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

References

Policy History
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022
08/01/2019 Medical Policy Committee review
08/14/2019 Medical Policy Implementation Committee approval. New policy.
08/06/2020 Medical Policy Committee review
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

08/12/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/16/2020 Coding update
08/05/2021 Medical Policy Committee review
08/04/2022 Medical Policy Committee review
08/10/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 8/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>15824, 15826, 64716, 64722, 64771, 64772, 67900</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>G43.00-G43.919, G44.00-G44.89, R51.10, R51.19</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company...
Surgical Deactivation of Headache Trigger Sites

Policy # 00683
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.